Click here to get full coverage on New expert consensus shifts RRP treatment from surgery to PAPZIMEOS - Stock Titan

New expert consensus shifts RRP treatment from surgery to PAPZIMEOS  Stock Titan

New expert consensus shifts RRP treatment from surgery to PAPZIMEOS - Stock Titan

Click here to get full coverage on Precigen Reports Third Quarter 2025 Financial Results and Business Updates - PR Newswire

Precigen Reports Third Quarter 2025 Financial Results and Business Updates  PR Newswire

Precigen Reports Third Quarter 2025 Financial Results and Business Updates - PR Newswire

Click here to get full coverage on Assessing Precigen (PGEN) Valuation After PAPZIMEOS Commercial Momentum And EMA Milestone - simplywall.st

Assessing Precigen (PGEN) Valuation After PAPZIMEOS Commercial Momentum And EMA Milestone  simplywall.st

Assessing Precigen (PGEN) Valuation After PAPZIMEOS Commercial Momentum And EMA Milestone - simplywall.st

Click here to get full coverage on A Look at Precigen (PGEN) Valuation Following FDA Approval of PAPZIMEOS for Recurrent Respiratory Papillomatosis - Yahoo Finance

A Look at Precigen (PGEN) Valuation Following FDA Approval of PAPZIMEOS for Recurrent Respiratory Papillomatosis  Yahoo Finance

A Look at Precigen (PGEN) Valuation Following FDA Approval of PAPZIMEOS for Recurrent Respiratory Papillomatosis - Yahoo Finance

Click here to get full coverage on HC Wainwright & Co. Maintains Precigen (PGEN) Buy Recommendation - Nasdaq

HC Wainwright & Co. Maintains Precigen (PGEN) Buy Recommendation  Nasdaq

HC Wainwright & Co. Maintains Precigen (PGEN) Buy Recommendation - Nasdaq

Click here to get full coverage on Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis - PR Newswire

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis  PR Newswire

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis - PR Newswire

Click here to get full coverage on Patient Capital Bets Big on Precigen (PGEN) By Acquiring 10.2 Million Shares - The Motley Fool

Patient Capital Bets Big on Precigen (PGEN) By Acquiring 10.2 Million Shares  The Motley Fool

Patient Capital Bets Big on Precigen (PGEN) By Acquiring 10.2 Million Shares - The Motley Fool

Click here to get full coverage on Precigen Is Still A Buy After The Papzimeos Rally (NASDAQ:PGEN) - Seeking Alpha

Precigen Is Still A Buy After The Papzimeos Rally (NASDAQ:PGEN)  Seeking Alpha

Precigen Is Still A Buy After The Papzimeos Rally (NASDAQ:PGEN) - Seeking Alpha

Click here to get full coverage on Insider Purchase: Chief Financial Officer of $PGEN Buys 2,932 Shares - Quiver Quantitative

Insider Purchase: Chief Financial Officer of $PGEN Buys 2,932 Shares  Quiver Quantitative

Insider Purchase: Chief Financial Officer of $PGEN Buys 2,932 Shares - Quiver Quantitative

Click here to get full coverage on Precigen’s (PGEN) Papzimeos Push Sparks Multibagger Ascent, Boosted by Analyst Optimism - Yahoo Finance

Precigen’s (PGEN) Papzimeos Push Sparks Multibagger Ascent, Boosted by Analyst Optimism  Yahoo Finance

Precigen’s (PGEN) Papzimeos Push Sparks Multibagger Ascent, Boosted by Analyst Optimism - Yahoo Finance

Click here to get full coverage on Trade Alert: Independent Director Of Precigen Jeffrey Kindler Has Sold Stock - simplywall.st

Trade Alert: Independent Director Of Precigen Jeffrey Kindler Has Sold Stock  simplywall.st

Trade Alert: Independent Director Of Precigen Jeffrey Kindler Has Sold Stock - simplywall.st

Click here to get full coverage on Precigen Announces Up to $125 Million Non-Dilutive Financing - PR Newswire

Precigen Announces Up to $125 Million Non-Dilutive Financing  PR Newswire

Precigen Announces Up to $125 Million Non-Dilutive Financing - PR Newswire

Click here to get full coverage on Cantor Fitzgerald Reaffirms Overweight Rating on Precigen (PGEN) - Yahoo Finance

Cantor Fitzgerald Reaffirms Overweight Rating on Precigen (PGEN)  Yahoo Finance

Cantor Fitzgerald Reaffirms Overweight Rating on Precigen (PGEN) - Yahoo Finance

Click here to get full coverage on PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug - Yahoo Finance

PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug  Yahoo Finance

PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug - Yahoo Finance

Click here to get full coverage on FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 - PR Newswire

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025  PR Newswire

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 - PR Newswire

Click here to get full coverage on H.C. Wainwright Remains Bullish on Precigen (PGEN) - Yahoo Finance

H.C. Wainwright Remains Bullish on Precigen (PGEN)  Yahoo Finance

H.C. Wainwright Remains Bullish on Precigen (PGEN) - Yahoo Finance

Click here to get full coverage on Precigen Inc (PGEN) Q3 2025 Earnings Call Highlights: FDA Approval and U.S. ... - Yahoo Finance

Precigen Inc (PGEN) Q3 2025 Earnings Call Highlights: FDA Approval and U.S. ...  Yahoo Finance

Precigen Inc (PGEN) Q3 2025 Earnings Call Highlights: FDA Approval and U.S. ... - Yahoo Finance

Click here to get full coverage on Precigen, Inc. (NASDAQ:PGEN): Is Breakeven Near? - Yahoo Finance

Precigen, Inc. (NASDAQ:PGEN): Is Breakeven Near?  Yahoo Finance

Precigen, Inc. (NASDAQ:PGEN): Is Breakeven Near? - Yahoo Finance

Click here to get full coverage on Precigen (PGEN) Secures FDA Approval for Papillomatosis Treatment - Yahoo Finance

Precigen (PGEN) Secures FDA Approval for Papillomatosis Treatment  Yahoo Finance

Precigen (PGEN) Secures FDA Approval for Papillomatosis Treatment - Yahoo Finance

Click here to get full coverage on Precigen (PGEN) Is Up 32.3% After FDA Approval of First Therapy for Recurrent Respiratory Papillomatosis - Yahoo Finance

Precigen (PGEN) Is Up 32.3% After FDA Approval of First Therapy for Recurrent Respiratory Papillomatosis  Yahoo Finance

Precigen (PGEN) Is Up 32.3% After FDA Approval of First Therapy for Recurrent Respiratory Papillomatosis - Yahoo Finance

Click here to get full coverage on Precigen (PGEN): Valuation in Focus After FDA Approval and Strengthened Cash Position - simplywall.st

Precigen (PGEN): Valuation in Focus After FDA Approval and Strengthened Cash Position  simplywall.st

Precigen (PGEN): Valuation in Focus After FDA Approval and Strengthened Cash Position - simplywall.st

Click here to get full coverage on Insider Purchase: Director at $PGEN Buys 10,645 Shares - Quiver Quantitative

Insider Purchase: Director at $PGEN Buys 10,645 Shares  Quiver Quantitative

Insider Purchase: Director at $PGEN Buys 10,645 Shares - Quiver Quantitative

Click here to get full coverage on Insider Sale: Director at $PGEN Sells 1,403,360 Shares | PGEN Stock News - Quiver Quantitative

Insider Sale: Director at $PGEN Sells 1,403,360 Shares | PGEN Stock News  Quiver Quantitative

Insider Sale: Director at $PGEN Sells 1,403,360 Shares | PGEN Stock News - Quiver Quantitative

Click here to get full coverage on $PGEN stock is up 8% today. Here's what we see in our data. - Quiver Quantitative

$PGEN stock is up 8% today. Here's what we see in our data.  Quiver Quantitative

$PGEN stock is up 8% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Precigen, Inc.'s (NASDAQ:PGEN) market cap touched US$455m last week, benefiting both private equity firms who own 33% as well as institutions - Yahoo Finance

Precigen, Inc.'s (NASDAQ:PGEN) market cap touched US$455m last week, benefiting both private equity firms who own 33% as well as institutions  Yahoo Finance

Precigen, Inc.'s (NASDAQ:PGEN) market cap touched US$455m last week, benefiting both private equity firms who own 33% as well as institutions - Yahoo Finance

Click here to get full coverage on Precigen (PGEN) director Kirk sells shares worth $12.3 million - Investing.com

Precigen (PGEN) director Kirk sells shares worth $12.3 million  Investing.com

Precigen (PGEN) director Kirk sells shares worth $12.3 million - Investing.com

Click here to get full coverage on Why Precigen, Inc. (PGEN) is Skyrocketing So Far in 2025 - Yahoo Finance

Why Precigen, Inc. (PGEN) is Skyrocketing So Far in 2025  Yahoo Finance

Why Precigen, Inc. (PGEN) is Skyrocketing So Far in 2025 - Yahoo Finance

Click here to get full coverage on Precigen, Inc. Stock (PGEN) Opinions on FDA Approval of Papzimeos | PGEN Stock News - Quiver Quantitative

Precigen, Inc. Stock (PGEN) Opinions on FDA Approval of Papzimeos | PGEN Stock News  Quiver Quantitative

Precigen, Inc. Stock (PGEN) Opinions on FDA Approval of Papzimeos | PGEN Stock News - Quiver Quantitative

Click here to get full coverage on Precigen: This Billion-Dollar Approval Is Still Undervalued (NASDAQ:PGEN) - Seeking Alpha

Precigen: This Billion-Dollar Approval Is Still Undervalued (NASDAQ:PGEN)  Seeking Alpha

Precigen: This Billion-Dollar Approval Is Still Undervalued (NASDAQ:PGEN) - Seeking Alpha

Click here to get full coverage on Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference - Investing News Network

Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference  Investing News Network

Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference - Investing News Network

Click here to get full coverage on The Outlook For Precigen (NASDAQ:PGEN) - Seeking Alpha

The Outlook For Precigen (NASDAQ:PGEN)  Seeking Alpha

The Outlook For Precigen (NASDAQ:PGEN) - Seeking Alpha

Click here to get full coverage on New Analyst Forecast: $PGEN Given $8.5 Price Target - Quiver Quantitative

New Analyst Forecast: $PGEN Given $8.5 Price Target  Quiver Quantitative

New Analyst Forecast: $PGEN Given $8.5 Price Target - Quiver Quantitative

Click here to get full coverage on Precigen stock surges on FDA approval (update) (PGEN:NASDAQ) - Seeking Alpha

Precigen stock surges on FDA approval (update) (PGEN:NASDAQ)  Seeking Alpha

Precigen stock surges on FDA approval (update) (PGEN:NASDAQ) - Seeking Alpha

Click here to get full coverage on Growth or Bubble? Decoding PGEN’s Rapid Rise - StocksToTrade

Growth or Bubble? Decoding PGEN’s Rapid Rise  StocksToTrade

Growth or Bubble? Decoding PGEN’s Rapid Rise - StocksToTrade

Click here to get full coverage on Precigen, Inc.'s (NASDAQ:PGEN) Profit Outlook - Yahoo Finance

Precigen, Inc.'s (NASDAQ:PGEN) Profit Outlook  Yahoo Finance

Precigen, Inc.'s (NASDAQ:PGEN) Profit Outlook - Yahoo Finance

Click here to get full coverage on Precigen Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st

Precigen Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags  simplywall.st

Precigen Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st

Click here to get full coverage on PGEN’s Roller Coaster Ride: What’s Next?​ - StocksToTrade

PGEN’s Roller Coaster Ride: What’s Next?​  StocksToTrade

PGEN’s Roller Coaster Ride: What’s Next?​ - StocksToTrade

Click here to get full coverage on Precigen, Inc. (PGEN) Secures $125M to Accelerate PAPZIMEOS Commercialization - Yahoo Finance

Precigen, Inc. (PGEN) Secures $125M to Accelerate PAPZIMEOS Commercialization  Yahoo Finance

Precigen, Inc. (PGEN) Secures $125M to Accelerate PAPZIMEOS Commercialization - Yahoo Finance

Click here to get full coverage on Precigen, Inc. (PGEN) Stock Analysis: Unlocking a 136% Upside Potential in Biotech Innovation - DirectorsTalk Interviews

Precigen, Inc. (PGEN) Stock Analysis: Unlocking a 136% Upside Potential in Biotech Innovation  DirectorsTalk Interviews

Precigen, Inc. (PGEN) Stock Analysis: Unlocking a 136% Upside Potential in Biotech Innovation - DirectorsTalk Interviews

Click here to get full coverage on Is Precigen (PGEN) The Hot Biotech Stock Under $5? - Yahoo Finance

Is Precigen (PGEN) The Hot Biotech Stock Under $5?  Yahoo Finance

Is Precigen (PGEN) The Hot Biotech Stock Under $5? - Yahoo Finance

Click here to get full coverage on Precigen, Inc. (PGEN) Stock Analysis: Unveiling A Remarkable 224% Upside Potential - DirectorsTalk Interviews

Precigen, Inc. (PGEN) Stock Analysis: Unveiling A Remarkable 224% Upside Potential  DirectorsTalk Interviews

Precigen, Inc. (PGEN) Stock Analysis: Unveiling A Remarkable 224% Upside Potential - DirectorsTalk Interviews

Click here to get full coverage on First-Ever FDA Approved Therapy: Precigen Leadership to Detail Breakthrough RRP Treatment at Key Events - Stock Titan

First-Ever FDA Approved Therapy: Precigen Leadership to Detail Breakthrough RRP Treatment at Key Events  Stock Titan

First-Ever FDA Approved Therapy: Precigen Leadership to Detail Breakthrough RRP Treatment at Key Events - Stock Titan

Click here to get full coverage on Precigen: August Is Pivotal For This Biotech Innovator - Seeking Alpha

Precigen: August Is Pivotal For This Biotech Innovator  Seeking Alpha

Precigen: August Is Pivotal For This Biotech Innovator - Seeking Alpha

Click here to get full coverage on Spotlighting Bridgewater Bancshares And 2 Other Growth Stocks With Strong Insider Ownership - simplywall.st

Spotlighting Bridgewater Bancshares And 2 Other Growth Stocks With Strong Insider Ownership  simplywall.st

Spotlighting Bridgewater Bancshares And 2 Other Growth Stocks With Strong Insider Ownership - simplywall.st

Click here to get full coverage on Vaxart (VXRT) and Precigen (PGEN) Shares Surge on Strong Q3 Earnings - GuruFocus

Vaxart (VXRT) and Precigen (PGEN) Shares Surge on Strong Q3 Earnings  GuruFocus

Vaxart (VXRT) and Precigen (PGEN) Shares Surge on Strong Q3 Earnings - GuruFocus

Click here to get full coverage on Precigen (PGEN) Analyst Rating Reiterated by HC Wainwright & Co. | PGEN Stock News - GuruFocus

Precigen (PGEN) Analyst Rating Reiterated by HC Wainwright & Co. | PGEN Stock News  GuruFocus

Precigen (PGEN) Analyst Rating Reiterated by HC Wainwright & Co. | PGEN Stock News - GuruFocus

Click here to get full coverage on Precigen Inc (PGEN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Seizing ... - Yahoo Finance

Precigen Inc (PGEN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Seizing ...  Yahoo Finance

Precigen Inc (PGEN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Seizing ... - Yahoo Finance

Click here to get full coverage on Precigen Inc (PGEN) Q3 2025 Earnings Call Highlights: FDA Approv - GuruFocus

Precigen Inc (PGEN) Q3 2025 Earnings Call Highlights: FDA Approv  GuruFocus

Precigen Inc (PGEN) Q3 2025 Earnings Call Highlights: FDA Approv - GuruFocus

Click here to get full coverage on Precigen Stock (PGEN) Roars Over 60% Higher on FDA Green Light for Papzimeos Therapy - TipRanks

Precigen Stock (PGEN) Roars Over 60% Higher on FDA Green Light for Papzimeos Therapy  TipRanks

Precigen Stock (PGEN) Roars Over 60% Higher on FDA Green Light for Papzimeos Therapy - TipRanks

Click here to get full coverage on Precigen (PGEN) Soars as PAPZIMEOS Launch, Q3 2025 Earnings and Fresh Analyst Upgrades Ignite Investor Interest - TechStock²

Precigen (PGEN) Soars as PAPZIMEOS Launch, Q3 2025 Earnings and Fresh Analyst Upgrades Ignite Investor Interest  TechStock²

Precigen (PGEN) Soars as PAPZIMEOS Launch, Q3 2025 Earnings and Fresh Analyst Upgrades Ignite Investor Interest - TechStock²

Click here to get full coverage on Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis - PR Newswire

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis  PR Newswire

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis - PR Newswire

Click here to get full coverage on Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement (PGEN) - Seeking Alpha

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement (PGEN)  Seeking Alpha

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement (PGEN) - Seeking Alpha

Click here to get full coverage on Precigen: Successful Proof Of Platform, But Cash Worries Remain (NASDAQ:PGEN) - Seeking Alpha

Precigen: Successful Proof Of Platform, But Cash Worries Remain (NASDAQ:PGEN)  Seeking Alpha

Precigen: Successful Proof Of Platform, But Cash Worries Remain (NASDAQ:PGEN) - Seeking Alpha

Click here to get full coverage on PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally? - Yahoo Finance

PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?  Yahoo Finance

PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally? - Yahoo Finance

Click here to get full coverage on Precigen (NASDAQ:PGEN shareholders incur further losses as stock declines 13% this week, taking five-year losses to 86% - Yahoo Finance

Precigen (NASDAQ:PGEN shareholders incur further losses as stock declines 13% this week, taking five-year losses to 86%  Yahoo Finance

Precigen (NASDAQ:PGEN shareholders incur further losses as stock declines 13% this week, taking five-year losses to 86% - Yahoo Finance

Click here to get full coverage on Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response - PR Newswire

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response  PR Newswire

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response - PR Newswire

Click here to get full coverage on Should You Invest in Precigen (PGEN)? - Yahoo Finance

Should You Invest in Precigen (PGEN)?  Yahoo Finance

Should You Invest in Precigen (PGEN)? - Yahoo Finance

Click here to get full coverage on Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics - PR Newswire

Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics  PR Newswire

Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics - PR Newswire

Click here to get full coverage on Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients - PR Newswire

Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients  PR Newswire

Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients - PR Newswire

Click here to get full coverage on Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock | PGEN Stock News - Stock Titan

Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock | PGEN Stock News  Stock Titan

Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock | PGEN Stock News - Stock Titan

Click here to get full coverage on Precigen (PGEN) - Zacks Investment Research

Precigen (PGEN)  Zacks Investment Research

Precigen (PGEN) - Zacks Investment Research

Click here to get full coverage on PGEN Stock Price and Chart — NASDAQ:PGEN - TradingView — Track All Markets

PGEN Stock Price and Chart — NASDAQ:PGEN  TradingView — Track All Markets

PGEN Stock Price and Chart — NASDAQ:PGEN - TradingView — Track All Markets

Click here to get full coverage on Precigen, inc (PGEN) Q2 2021 Earnings Call Transcript - The Motley Fool

Precigen, inc (PGEN) Q2 2021 Earnings Call Transcript  The Motley Fool

Precigen, inc (PGEN) Q2 2021 Earnings Call Transcript - The Motley Fool

Click here to get full coverage on Here's Why Precigen, Inc. (PGEN) Could be Great Choice for a Bottom Fisher - Yahoo Finance

Here's Why Precigen, Inc. (PGEN) Could be Great Choice for a Bottom Fisher  Yahoo Finance

Here's Why Precigen, Inc. (PGEN) Could be Great Choice for a Bottom Fisher - Yahoo Finance

Click here to get full coverage on Origins of De Novo Genes in Human and Chimpanzee - PLOS

Origins of De Novo Genes in Human and Chimpanzee  PLOS

Origins of De Novo Genes in Human and Chimpanzee - PLOS

Click here to get full coverage on DNA Methylation of the Gonadal Aromatase (cyp19a) Promoter Is Involved in Temperature-Dependent Sex Ratio Shifts in the European Sea Bass - PLOS

DNA Methylation of the Gonadal Aromatase (cyp19a) Promoter Is Involved in Temperature-Dependent Sex Ratio Shifts in the European Sea Bass  PLOS

PGEN

Price Chart

Key Statistics

Technicals

About PGEN

Latest News

New expert consensus shifts RRP treatment from surgery to PAPZIMEOS - Stock Titan

Precigen Reports Third Quarter 2025 Financial Results and Business Updates - PR Newswire

Assessing Precigen (PGEN) Valuation After PAPZIMEOS Commercial Momentum And EMA Milestone - simplywall.st

Advanced Charts

Top Gainers

Top Losers